Éric Lévesque
Chercheur universitaire clinicien
Axe Endocrinologie et néphrologie
Métastases et progression du cancer
Tumeurs cancéreuses solides
Urologie
Oncologie clinique
Pharmacogénomique
Dernières nouvelles
Publications
Voir tout-
article Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…
Can Urol Assoc J 2026.
-
article Feng T, Xie N, Gao L, Jia Q, Kung SH, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression
J Clin Invest 136 (2), 2026.
-
article Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É and Guillemette C
Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer
BMC Cancer 25 (1), 2025.
Projets
- Découverte de biomarqueurs pronostiques et prédictifs en cancer de la prostate., du 2024-05-22 au 2027-05-22
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, du 2023-09-01 au 2025-08-31